| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CARD17 |
| Uniprot No | Q5XLA6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-110aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMADKVLKEKRKQFIRSVGEGTINGLLG ELLETRVLSQEEIEIVKCENATVMDKARALLDSVIRKGAPACQICITYIC EEDSHLAGTLGLSAGPTSGNHLTTQDSQIVLPS |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CARD17重组蛋白的3篇文献示例(注：文献为虚构示例，实际研究请参考真实数据库)：
1. **文献名称**：*Structural and Functional Characterization of Recombinant CARD17 Protein in Apoptosis Regulation*
**作者**：Smith J, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了重组CARD17蛋白，证实其通过抑制caspase-9的激活参与细胞凋亡调控，并揭示了其CARD结构域的关键作用。
2. **文献名称**：*CARD17 Recombinant Protein Modulates NF-κB Signaling in Inflammatory Responses*
**作者**：Zhang Y, et al.
**摘要**：通过哺乳动物细胞系统表达重组CARD17蛋白，发现其通过结合TRAF2蛋白调控NF-κB信号通路，在炎症反应中发挥潜在抑制作用。
3. **文献名称**：*Expression and Interaction Mapping of CARD17 in the Caspase Activation Network*
**作者**：Lee S, et al.
**摘要**：利用重组CARD17蛋白进行蛋白质互作实验，揭示了其与凋亡相关蛋白(如APAF-1)的相互作用，为CARD家族蛋白的功能多样性提供了新证据。
如需真实文献，建议在PubMed或Google Scholar中搜索关键词“CARD17 recombinant protein”或“CASP17(别名)”获取最新研究。
**Background of CARD17 Recombinant Protein**
CARD17. also known as Caspase Recruitment Domain Family Member 17. is a protein encoded by the *CARD17* gene in humans. It belongs to the CARD protein family, characterized by a caspase recruitment domain (CARD), a structural motif involved in homotypic protein interactions that regulate apoptosis, inflammation, and immune signaling. CARD17 is primarily studied for its role as a regulatory component in innate immunity and inflammatory pathways, particularly through its interaction with caspases, which are cysteine proteases critical for programmed cell death and cytokine maturation.
Functionally, CARD17 acts as a modulator of caspase-1 activity, a key enzyme in the NLRP3 inflammasome complex responsible for processing pro-inflammatory cytokines like IL-1β and IL-18. Unlike some CARD family proteins that promote caspase activation, CARD17 is proposed to act as an inhibitory checkpoint, dampening excessive inflammasome signaling to prevent pathological inflammation. This regulatory mechanism suggests its potential involvement in autoimmune disorders, infectious diseases, or conditions linked to dysregulated immune responses.
Recombinant CARD17 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its structure-function relationships, interactions with binding partners, and therapeutic potential. Its recombinant form often includes tags (e.g., His-tag) for purification and detection. Research applications include *in vitro* binding assays, structural studies (e.g., X-ray crystallography), and screening for small-molecule inhibitors or activators targeting CARD17-mediated pathways.
Despite progress, the precise biological context of CARD17 remains under investigation. Challenges include elucidating tissue-specific expression, post-translational modifications, and cross-talk with other CARD proteins (e.g., CARD18). Understanding CARD17’s role in health and disease could unveil novel strategies for treating inflammation-driven pathologies.
×
